FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED (FPH)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:

FPH - FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED
FNArena Sector :
Medical Equipment & Devices
Year End: March
GICS Industry Group : Health Care Equipment & Services
Index: ASX100 | ASX200 | ASX300 | ALL-ORDS
FNArena Sector : Medical Equipment & Devices
Year End: March
Fisher & Paykel Healthcare is a designer and manufacturer of systems used in respiratory care and treatment of sleep disorders. It was separated from Fisher & Paykel and listed on the ASX and NZX in 2001. A brief Nasdaq listing was terminated in 2003. Only 1% of its revenues stems from New Zealand.
LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
---|---|---|---|
$18.78
17 May |
OPEN $18.97 |
HIGH $18.97 |
392,123 LOW $18.57 |
TARGET | |||||
|
|||||
Franking for last dividend paid out: 0% |
OTHER COMPANIES IN THE SAME SECTOR | |||
ELX . PGC . AHZ . COH . IPD . LHC . NAN . RMD . SOM . HLA . MX1 . CAT . VHT . ONE . IDX . PME . CSX . 4DX . BRN . EMV . UBI . LDX . RAP . RVA . MEB . IME . PCK . CMP . CYC . IMR . VTI . OVN . EYE . CGS . CU6 . TRJ . EBR . AT1 . CBL . |
FNARENA'S MARKET CONSENSUS FORECASTS
Title | FY22 Forecast |
FY23 Forecast |
---|---|---|
EPS (cps) | 71.1 | xxx |
DPS (cps) | 36.4 | xxx |
EPS Growth | N/A | xxx |
DPS Growth | N/A | xxx |
PE Ratio | 26.8 | xxx |
Dividend Yield | 1.9% | xxx |
Div Pay Ratio(%) | 51.2% | xxx |
All estimates have been converted into AUD by FNArena at present FX values.
Last ex-div: 02/12 - ex-div 16.28c (franking 0%)
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2022 FactSet UK Limited. All rights reserved
Title | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|---|---|
EPS Basic | xxx | xxx | xxx | xxx | xxx | 85.3 |
DPS All | xxx | xxx | xxx | xxx | xxx | 41.7 |
Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 1,819.2 M |
Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 242.7 |
Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | 583.9 M |
Net Profit Margin | xxx | xxx | xxx | xxx | xxx | 26.91 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
Title | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|---|---|
Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | 41.81 % |
Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | 39.65 % |
Return on Assets | xxx | xxx | xxx | xxx | xxx | 29.68 % |
Return on Equity | xxx | xxx | xxx | xxx | xxx | 41.81 % |
Return on Total Capital | xxx | xxx | xxx | xxx | xxx | 49.85 % |
Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | 265.0 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
This is work in progress. Bear with us. It'll be amazing.
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
FPH STOCK CHART

FNArena News on FPH
1 |
April In Review: ASX Defensives ShineMay 04 2022 - Australia |
2 |
March In Review: War Puts ASX On PedestalApr 06 2022 - Australia |
3 |
Australian Broker Call *Extra* Edition – Mar 29, 2022Mar 29 2022 - Daily Market Reports |
4 |
Australian Broker Call *Extra* Edition – Mar 28, 2022Mar 28 2022 - Daily Market Reports |
5 |
Opportunity for Fisher & Paykel HealthcareMar 25 2022 - Australia |
Latest Medical Equipment & Devices News
1 |
Shortages Chip Away At ResMed’s Big BreakMar 30 2022 - Australia |
2 |
Opportunity for Fisher & Paykel HealthcareMar 25 2022 - Australia |
3 |
Distribution Anxiety For NanosonicsFeb 10 2022 - Australia |
4 |
Brokers Awake To ResMed’s PotentialJan 31 2022 - Australia |
5 |
Covid Benefits F&P Healthcare, For NowDec 06 2021 - Australia |
6 |
Will Shortages Limit Upside For ResMed?Nov 01 2021 - Australia |
7 |
Nanosonics Unveils Its New ProductAug 26 2021 - Australia |
8 |
Pro Medicus: Opportunity AwaitsAug 24 2021 - Technicals |
9 |
Breakout For CochlearAug 10 2021 - Technicals |
10 |
Will ResMed’s Market Share Gains Last?Aug 09 2021 - Australia |